CA-THEOREMONE
Theorem, LLC, innovation and engineering partner to the Global 1000, today announced that it has rebranded to TheoremOne® following an acquisition of Formula Partners , and launch of its near-shore, pureplay software engineering service, Lemma . The new name positions TheoremOne as the foundation of a family of brands designed to help enterprises build better, more innovative business platforms at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005847/en/
“Our new name positions TheoremOne as the foundation of a family of brands, all inspired by our hypothesis driven model for innovation. Each brand is designed to address the specific needs of our clients at different moments in the lifecycle of enterprise innovation,” said Brady Brim-DeForest, CEO of TheoremOne.
Its newest acquisition, Formula Partners, helps companies create new models for organizational design, continuous improvement, and visionary leadership. Formula Partner’s approach revolves around a modular innovation process called the New Enterprise™, a proprietary model for modern consulting at the nexus of technology and organizational transformation. Formula Partners will become a new independent line of business and will operate under the “Formula Partners” brand.
“We are approaching management consulting from 14 years of implementing technology solutions — giving us a deep understanding of the true benefits (and costs) of making strategic recommendations. We’ve built trust with IT and business leaders through hands-on work, and we’re excited to build even broader strategic relationships through Formula Partners,” said Will Jessup, Head of Services Delivery at TheoremOne.
TheoremOne has also launched a new engineering service called Lemma. Lemma offers pureplay software engineering teams staffed exclusively by nearshore engineering talent. Lemma shares a common engineering DNA with TheoremOne but is designed to deliver engineering capacity as a modular service offering that can be deployed to scale existing teams and initiatives for enterprise and growth stage clients.
“Lemma fills a gap in our offerings that the market has illuminated over the last few years,” said Alex Finnemore, TheoremOne’s Head of Revenue. “It’s a compelling option for clients that have already determined the right way to solve a business problem and need a dedicated technology partner, but want to provide their own product, design, and leadership talent.”
Lemma and Formula Partners will join existing divisions Proof (staff augmentation) and Halmos Ventures (innovation incubation) in rounding out TheoremOne’s end-to-end services stack.
As part of the name change, TheoremOne has released a new company logo and launched a new website at www.theoremone.co .
About TheoremOne®
TheoremOne is an innovation and engineering firm that builds custom software for companies making bold bets to stay ahead. Through research, lean design, and agile delivery, TheoremOne makes great user experiences accessible to the enterprise. Founded in 2007, TheoremOne’s global cross-functional product development teams drive technology, process, and cultural transformation. To learn more about how TheoremOne enables ambitious leaders to build better software visit www.theoremone.co or follow @TheoremOne
About Formula Partners
Formula Partners is a different kind of management consulting firm — it targets the intersection of technology and organizational transformation, unlocking models for continuous improvement, and enabling visionary leadership within the enterprise. Founded in 2015, Formula Partners is based in Los Angeles. Read more at: www.formula.partners .
About Lemma
Lemma offers pureplay software engineering teams designed to deliver high-quality results at-scale. Clients come to Lemma when they need an injection of fully-managed and modular engineering talent. Learn more about Lemma at: www.thinklemma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005847/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom